Commentary

Why is vitamin D hype so impervious to evidence?


 

Conclusion: No, it is not hopeless

A nihilist would argue that fighting spin is futile. They would say you can’t fight incentives and business models. The incentive structure to publish is strong, and the journals and media know vitamin D studies garner attention – which is their currency.

I am not a nihilist and believe strongly that we must continue to teach critical appraisal and numerical literacy.

In fact, I would speculate that decades of poor critical appraisal by the medical profession have fostered outsized hope and created erroneous norms.

Imagine a counter-factual world in which clinicians have taught society that the human body is unlike an engine that can be repaired by fixing one part (i.e., the vitamin D level), that magic bullets (insulin) are rare, that most treatments fail, or that you can’t rely on association studies to prove efficacy.

In this world, people would be immune from spin and hype.

The norm would be that pills, supplements, and procedures are not what delivers good health. What delivers health is an amalgam of good luck, healthy habits, and lots of time spent outside playing in the sun.

Dr. Mandrola practices cardiac electrophysiology in Louisville, Ky., and is a writer and podcaster for Medscape. He espouses a conservative approach to medical practice. He participates in clinical research and writes often about the state of medical evidence. He has disclosed no relevant financial relationships. A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Mask-wearing cuts new COVID-19 cases by 53%, study says
MDedge Rheumatology
FDA authorizes COVID boosters for all U.S. adults
MDedge Rheumatology
CDC unveils mental health protection plan for health care workers
MDedge Rheumatology
Penicillin slows latent rheumatic heart disease progression
MDedge Rheumatology
Specialists think it’s up to the PCP to recommend flu vaccines. But many patients don’t see a PCP every year
MDedge Rheumatology
Risk for severe COVID-19 and death plummets with Pfizer booster
MDedge Rheumatology
FDA backs Pfizer booster for 12- to 15-year-olds
MDedge Rheumatology
Oral penicillin advised for high-risk rheumatic heart disease
MDedge Rheumatology
Presence of autoantibodies most predictive of long COVID in study
MDedge Rheumatology
Vitamin D shows no survival benefit in nondeficient elderly
MDedge Rheumatology